TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 303 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q2 2021. The put-call ratio across all filers is 0.61 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $18,000 | -10.0% | 1,291 | -9.3% | 0.00% | 0.0% |
| Q1 2022 | $20,000 | +400.0% | 1,424 | +376.3% | 0.00% | +300.0% |
| Q4 2021 | $4,000 | -85.7% | 299 | -82.5% | 0.00% | -80.0% |
| Q3 2021 | $28,000 | +3.7% | 1,707 | +5.0% | 0.01% | 0.0% |
| Q2 2021 | $27,000 | -18.2% | 1,625 | -10.9% | 0.01% | -37.5% |
| Q1 2021 | $33,000 | -57.1% | 1,823 | -57.0% | 0.01% | -57.9% |
| Q4 2020 | $77,000 | +185.2% | 4,240 | +181.4% | 0.02% | +111.1% |
| Q3 2020 | $27,000 | 0.0% | 1,507 | 0.0% | 0.01% | -10.0% |
| Q2 2020 | $27,000 | +68.8% | 1,507 | +41.8% | 0.01% | +42.9% |
| Q1 2020 | $16,000 | +77.8% | 1,063 | +135.2% | 0.01% | +133.3% |
| Q4 2019 | $9,000 | +12.5% | 452 | 0.0% | 0.00% | -25.0% |
| Q3 2019 | $8,000 | +14.3% | 452 | +8.7% | 0.00% | +33.3% |
| Q2 2019 | $7,000 | 0.0% | 416 | +25.7% | 0.00% | -25.0% |
| Q1 2019 | $7,000 | – | 331 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 9,270,535 | $188,841,000 | 39.13% |
| Sachem Head Capital | 5,963,600 | $121,479,000 | 7.38% |
| NINE MASTS CAPITAL Ltd | 1,049,886 | $21,415,000 | 6.68% |
| Paulson & Co. | 26,489,422 | $539,590,000 | 5.77% |
| Blackcrane Capital, LLC | 189,549 | $3,861,000 | 5.16% |
| Glenview Capital Management | 26,112,660 | $531,915,000 | 4.75% |
| Exane Asset Management | 430,369 | $8,766,617,000 | 4.26% |
| Velanne Asset Management Ltd | 281,972 | $5,744,000 | 3.97% |
| Bluefin Trading, LLC | 1,204,702 | $24,540,000 | 3.55% |
| Endurant Capital Management LP | 437,436 | $8,911,000 | 3.52% |